Cellceutix Makes Breakthrough in Cancer Research by Activating p53, the “Guardian Angel of the Human Genome”

Learn more »

Clinical Trials at Dana-Farber and Beth Israel Deaconess / Harvard Cancer Centers

Learn more »

Prurisol for Psoriasis Planned- Phase 2/3 under FDA 505(b)(2)

Learn more »

Dr. Emil Frei: “What Cellceutix is doing with Kevetrin can lead to a groundbreaking moment in the world of oncology…”

Learn more »

Leading Antibiotic Technologies Licensed From University of Pennsylvania

Learn more »

Cellceutix Takes on Klebsiella Pneumoniae, One of the World’s Most Dangerous Superbugs

Learn more »

From the CEO’s Desk

CELLCEUTIX PROVIDES UPDATE TO SHAREHOLDERS 

My Fellow Cellceutix Shareholders,

We are pleased to inform you that this past Thursday (February 5th)  we submitted an application to the NASDAQ Exchange for listing on the NASDAQ Capital Markets.  We have already met ...

Read More »

Our Technology

Kevetrin
Our technology - Kevetrin™ targets both MDM2-p53 and Rb-E2F pathways in tumor suppression.

Read more »

Prurisol
Our technology KM-133 acts through immune modulation and PRINS reduction

Read more »

Brilacidin
Our technology - Brilacidin is the first of a completely new class of antibiotics called defensin-mimetics

Read more »

Email Alerts

Sign Up to Receive Alerts on Cellceutix click here.

Clinical Trials

More information available at clinicaltrials.gov






Visit Us On TwitterVisit Us On FacebookVisit Us On Linkedin